Chemotherapy drug shortages have become a persistent and serious challenge in cancer care, affecting millions of patients across the United States. These shortages disrupt treatment schedules, force substitutions with less optimal drugs, and add significant anxiety to patients already facing life-threatening illnesses1 2. Despite some improvements, many essential chemotherapy drugs remain in short supply, threatening patient outcomes and increasing healthcare costs3 .
Causes of Current Chemotherapy Shortages
The current chemotherapy drug shortages primarily involve older, off-patent generic injectable cancer drugs. These essential medicines often have low prices and thin profit margins, which discourage manufacturers from investing in modern production facilities or maintaining redundant manufacturing capacity4 56. Manufacturing problems, such as quality control failures and plant shutdowns, are frequent contributors to supply disruptions4 7. For example, the cisplatin and carboplatin shortages in recent years were linked to manufacturing halts at key production sites8 7.
Beyond manufacturing issues, several systemic factors contribute to shortages:
- Low prices and profit margins: Generic oncology drugs are often sold at prices that do not support sustainable manufacturing investments5 9.
- Supply chain complexity: The active pharmaceutical ingredients (APIs) and finished products are often produced in a limited number of facilities, sometimes concentrated in a single country, increasing vulnerability to disruptions9 .
- Regulatory and quality challenges: Inspections revealing quality lapses can lead to production halts, further reducing supply7 .
- Demand fluctuations and panic buying: Awareness of impending shortages can trigger stockpiling, exacerbating supply imbalances10 .
- Downward price pressure from group purchasing organizations (GPOs): These middlemen negotiate aggressively for low prices, which can drive manufacturers out of the market7 .
These factors combine to create a fragile supply system where even minor disruptions can lead to prolonged shortages11 9.
“Every clinician I know would be thrilled to pay more money for a reliable supply of a quality drug.”
— Dr. Andrew Shuman, University of Michigan7
Treatment Disruptions from Drug Shortages
Drug shortages have led to significant treatment disruptions in oncology practice. Hospitals and oncologists frequently report delays in chemotherapy cycles, therapy switches, or both, which can compromise patient safety and clinical outcomes12 13. In Botswana, a retrospective cohort study found that during drug stockouts, 67.2% of events involved treatment delays, 24.4% involved switching drugs, and 8.4% involved both13 . Breast cancer patients were notably affected by substitutions such as docetaxel replacing paclitaxel13 .
In the United States, surveys indicate that the majority of oncology providers have experienced shortages that forced changes in treatment regimens, including dose reductions, delayed cycles, or use of alternative drugs with potentially greater side effects or lower efficacy12 2. These adjustments can increase healthcare costs and complicate clinical management12 .
Ethical dilemmas arise when deciding how to allocate scarce drugs. Frameworks emphasize prioritizing patients with curative intent or highest clinical need, but applying these principles in practice can be challenging14 2.
“We’re calling it a maldistribution based on who has access
— who can afford to create a little stockpile at their site.” — Dr. Julie Gralow, American Society of Clinical Oncology7
Related Stories
Patient Risks of Chemotherapy Shortages
Chemotherapy drug shortages pose serious risks to patients, including treatment delays, use of less effective or more toxic alternatives, and increased anxiety during an already stressful experience1 15. A survey by the American Cancer Society Cancer Action Network found that 10% of cancer patients in active treatment reported being impacted by drug shortages, with Medicaid enrollees disproportionately affected at 22% 15. Among those impacted, 45% experienced treatment delays, and 68% had difficulty finding effective substitute medications15 .
These disruptions can lead to poorer disease control, increased side effects, and potentially reduced survival, especially when first-line curative treatments are unavailable13 16. For example, shortages of platinum-based drugs like cisplatin and carboplatin, which are critical for treating multiple cancers, have forced clinicians to use less effective alternatives, raising concerns about inferior outcomes13 9.
Patients also face logistical challenges, such as traveling long distances to find available drugs or dealing with insurance coverage issues for substitute therapies15 . The emotional toll is significant, with patients reporting increased stress, fear, and frustration7 .
“For providers, shortages undoubtedly disrupt practice. For patients needing chemotherapy treatment, a shortage adds anxiety to an already stressful and complicated experience. It may even impact the patient's course of treatment and, in some instances, survival.” — 1
Chemotherapy Drug Supply and Demand
The supply and demand dynamics of chemotherapy drugs contribute to the ongoing shortage crisis. Older generic injectable cancer drugs often have low prices, which limit manufacturer incentives to maintain or expand production capacity17 9. The complexity of manufacturing sterile injectable drugs, combined with geographic concentration of production facilities, increases supply vulnerability9 .
Shortages compromise the sustainability of drug supply, as health systems must source alternatives or import medicines under unfavorable financial conditions18 . This can negatively impact disease control and quality of life for patients with oncohematological malignancies18 . Additionally, clinical trials evaluating novel agents in combination with standard chemotherapy drugs are affected, potentially delaying research progress12 .
A vulnerability score system developed by the United States Pharmacopeia (USP) highlights that many essential oncology drugs have supply chains at high risk of disruption due to factors such as low price, manufacturing complexity, and geographic concentration9 . For example, cisplatin and carboplatin have consistently high vulnerability scores and have experienced prolonged shortages9 .
| Drug (Form) | Production Location Concentration (2025) | Vulnerability Score (%) | FDA Shortage Status (May 2025) |
|---|---|---|---|
| Cisplatin (injectable) | 42% India | 79.1 | Discontinued |
| Carboplatin (injectable) | Data not specified | High (implied) | Currently in shortage |
| Nivolumab (injectable) | 100% United States | NA | Not in shortage |
9
Solutions for Chemotherapy Drug Shortages
“We've made so many treatment advances in the last decade that are extending survival and improving quality of life for patients with cancer. Chemotherapy drugs are among the most important medicines we use, and they’re one of the most important tools I have as an oncologist to help my patients.”
— Amanda Nickles Fader, MD, Johns Hopkins School of Medicine3
Addressing chemotherapy drug shortages requires a multipronged approach involving regulatory agencies, manufacturers, healthcare providers, and policymakers. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have implemented measures such as early-warning systems and expedited approvals to mitigate shortages19 11. The FDA also requires manufacturers to notify impending shortages, enabling early intervention20 .
Key strategies proposed and underway include:
- Improving manufacturing quality and capacity: Federal grants and incentives can help manufacturers upgrade facilities and adopt advanced manufacturing technologies10 .
- Establishing drug reserves: Stockpiling critical drugs and active pharmaceutical ingredients as buffer supplies managed by manufacturers can help prevent shortages10 .
- Onshoring production: Bringing manufacturing closer to the US market can improve supply chain resilience, though it is not a complete solution10 9.
- Creating vulnerable medicines lists (VMLs): Identifying essential drugs at risk of shortage helps prioritize resources and incentives9 .
- Revising reimbursement models: Incentivizing supply chain resilience through payment reforms can encourage manufacturers to maintain reliable production21 .
- Enhancing supply chain transparency: Investing in data systems and predictive analytics to anticipate shortages and coordinate responses9 .
- Advocacy and coalition building: Engaging patient advocates, clinicians, and policymakers to raise awareness and push for legislative action9 .
“Ending drug shortages will require a trusted patient advocacy partner to bridge industry, government, health care, and patient needs
— ensuring continuity of care.” — Kenneth M. Komorny, PharmD, Moffitt Cancer Center2
Cancer centers and community oncology practices have also adopted clinical strategies to manage shortages, such as limiting use of scarce drugs, prioritizing patients with curative intent, extending treatment intervals, and using alternative regimens when necessary2 . These efforts, combined with regulatory actions, have helped alleviate some shortages but underscore the need for systemic solutions2 .
